that inhibited further development of this class of compounds (for a review, see ref. 4 ). More recent evidence reveals that, in some cases, TRPV1 blockade also produced hypothermia [4] . The clinical question of whether blocking TRPV1 could produce analgesic benefit for patients was thus never fully answered.
The opioid epidemic has yet another side. Millions of surgeries are performed annually in the United States and around the world. As population growth accelerates, and as our citizens age, the numbers of surgeries performed will undoubtedly increase further. An often underappreciated factor in opioid dependence and addiction is persistent opioid use after surgical procedures in a vulnerable population. A recent study published in JAMA Surgery demonstrated that incidence of new persistent opioid use (continued opioid use beyond 3 months postsurgery) is as high as 5-6% [5] . These patients were opioid-na€ ıve prior to the surgery, and, interestingly, the persistence of opioid use was independent of the initial severity of the surgery. Thus, each year, millions of opioidna€ ıve patients are at risk of becoming opioid-dependent.
During surgery, patients often exhibit a significant decrease in core body temperature (i.e., hypothermia) while under anesthesia. Anesthesia-induced hypothermia is associated with a number of significant health-related problems, including increased surgical site infection, increased bleeding, poor wound healing and overall slower recovery with longer hospital stays and increased pain. These complications result in an economic impact of millions of dollars in healthcare costs, as well as loss of work hours and increased suffering for patients, further impacting the healthcare system. Anesthesia-induced hypothermia is currently managed by physical means involving attempts to warm the patient with forced-air warming blankets or with infusions of warm fluids. However, these means can be inadequate in many larger surgeries and can be associated with their own complications such as risk of burn injury. Currently, no pharmacological treatment exists for anesthesia-induced hypothermia.
We recently proposed to use the hyperthermic effect, a major side effect of many TRPV1 antagonists, to counteract anesthesia-induced hypothermia [6] . We demonstrated that TRPV1 antagonists may be repurposed to prevent or treat surgical anesthesia-induced hypothermia, while also reducing post-surgery opioid requirements in rodents [6] . We also paved a way of how to convert this idea and our preclinical findings into a drug [7] . The potential use of TRPV1 antagonists to treat this important problem not only will be the first pharmacological approach, but it may have important implications for reducing opioid use in the post-surgery period and thus helping to limit the extent of the opioid epidemic.
There are potentially other ways of utilizing various properties of TRPV1 antagonists for drug development. For example, those compounds that do not affect body temperature (i.e., cause neither hyperthermia nor hypothermia) can continue being evaluated as potential analgesics, and several pharmaceutical companies are working in this direction. A more speculative application would be to repurpose the hypothermia-inducing TRPV1 antagonists for the induction of therapeutic hypothermia, perhaps to replace TRPV1 agonists, which have been proposed for this purpose [8] . As in the case of using the hyperthermic effect of TRPV1 antagonists to counteract the hypothermic action of anesthesia, using their hypothermic effect in therapeutic hypothermia may come with added benefits of analgesia and reduction of opioid use. All these proposed uses are consistent with the Federal Pain Research Strategy and the goals of the NIH to reconsider "shelved non-opioid analgesics", including TRPV1 antagonists-compounds that are widely known to affect body temperature. Note 1. Due to the strict limit to the number of references, we cite some statistics and widely known facts related to the use of opioids without supporting them with proper references.
